Nuberol Forte

PreclinicalSmall molecule

TThe Searle Company Limited Pakistan

Nuberol Forte is one of 7 small molecule programs targeting Chronic Neck Pain. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Neck PainActive, not recruiting

Chronic Neck PainPreclinical

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Chronic Neck Pain

#DrugCompanyPhaseTrials

Aspercreme Warming

AAveritas Pharma, Inc.

Approved

1 2

Amitryptiline

SSt Joseph University, Beirut, Lebanon

Approved

1 3

Versed

CConrado Roberto Hoffmann Filho

Phase 1

1 4

Tylenol

KKenvue Brands

Preclinical

1 5

Botulinum Toxins

YYale University

Phase 1

1 6

Conventional Medication

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Preclinical

1 7

Nuberol Forte

TThe Searle Company Limited Pakistan

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Neck Pain1 trial

Clinical Response of Nuberol Forte in Chronic Neck Pain in Routine Rehabilitation Centers

Completed·TThe Searle Company Limited Pakistan··NCT06628466·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Nuberol Forte. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nuberol Forte compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nuberol Forte. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Searle Company Limited Pakistan company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TThe Searle Company Limited Pakistan

Nuberol Forte

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Neck Pain1 trial

References

Drug Info

Quick Facts

Related News